Wenjie Zhang

Dr. Wenjie Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2025 in iLIVER
Verified
Journal Article
Open access
CGChuheng Gou
Chuheng Gou
WZWenjie Zhang
Wenjie Zhang
HXHao Xu
Hao Xu
HZHong Zhang
Hong Zhang
RDRui Ding
Rui Ding
XZXuan Zhang
Xuan Zhang
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than a quarter of adults worldwide. MASLD is associated with severe medical burdens and leads to further reduction of the donor pool for liver transplantation. However, there is a lack of systematic evaluation of the pathogenesis of MASLD development and MASLD graft damage. As a multisystem disorder, the pathogenesis of MASLD is closely related to genetics, metabolic and endocrine disorders, imbalanced intestinal flora, abnormal hepatocyte homeostasis, and hepatic inflammation. Mutations or single nucleotide polymorphisms and epigenetic modifications in multiple genes increase a person's susceptibility to developing MASLD. Lipid accumulation is a central pathogenic driver, and intestinal microbiota and endocrine disorders can exacerbate steatosis and inflammation. These issues cause endoplasmic reticulum stress in hepatocytes, leading to apoptosis and promoting the recruitment and activation of immune cells. Ultimately, hepatic stellate cells are activated, resulting in liver fibrosis. These molecular and pathological changes are important causes of why a MASLD donor liver is likely to suffer ischemia-reperfusion injury and cold ischemic injury. Lipid deposition, microcirculation disturbance, and inflammation in the MASLD donor liver exacerbates ischemia-reperfusion-related damage. During transplantation, cold ischemia time should be minimized, and machine perfusion implemented and treatments for MASLD used after transplantation to protect the graft. This systematic review describes the pathogenesis of MASLD and the mechanism of MASLD donor liver damage to potentially increase the use of MASLD donor livers and provide strategies to preserve organ function.

1 December 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
QMqiang meng
qiang meng
WWWeikang Wu
Weikang Wu
WZWenjie Zhang
Wenjie Zhang
JYJuzheng Yuan
Juzheng Yuan
LYLong Yang
Long Yang
TKTao Kaishan
Tao Kaishan
Interleukin-18 (IL-18) can effectively activate natural killer (NK) cells and induce large concentrations of interferon-γ (IFN-γ). In healthy humans, IL-18 binding protein (IL-18BP) can inhibit the binding of IL-18 to IL-18R and counteract the biological action of IL-18 due to its high concentration and high affinity, thus preventing the production of IFN-γ and inhibiting NK-cell activation. Through previous studies and the phenomena observed by our group in pig–non-human primates (NHPs) liver transplantation experiments, we proposed that the imbalance in IL-18/IL-18BP expression upon transplantation encourages the activation, proliferation, and cytotoxic effects of NK cells, ultimately causing acute vascular rejection of the graft. In this research, we used Lewis–Brown Norway rat orthotopic liver transplantation (OLTx) as a model of acute vascular rejection. AAV8-Il18bp viral vectors as gene delivery vehicles were constructed for gene therapy to overexpress IL-18BP and alleviate NK-cell rejection of the graft after transplantation. The results showed that livers overexpressing IL-18BP had reduced damage and could function longer after transplantation, effectively improving the survival time of the recipients.

5 May 2023 in Shock
Verified
Journal Article
Open access
KNKunwei Niu
Kunwei Niu
LYLong Yang
Long Yang
WSWenjie Song
Wenjie Song
ZLZhengcai Liu
Zhengcai Liu
JYJuzheng Yuan
Juzheng Yuan
TKTao Kaishan
Tao Kaishan
Objective: Histone deacetylase inhibitors (HDACIs) have been reported to improve survival in rats with hemorrhagic shock (HS). However, no consensus exists on the most effective HDACIs and their administration routes. We herein aimed to determine the optimal HDACIs and administration route in rats with HS. Methods: Survival analysis: In experiment I, male Sprague-Dawley rats were subjected to HS (mean arterial pressure [MAP] was maintained at 30–40 mm Hg for 20 min), and intravenously injected with the following agents (n = 8 per group): (1) no treatment, (2) vehicle (VEH), (3) entinostat (MS-275), (4) [N-((6-(Hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide] (LMK-235), (5) tubastatin A, (6) trichostatin A (TSA), and (7) sirtinol. In experiment II, rats were intraperitoneally injected with TSA. Mechanism research: In experiments I and II, rats were observed for 3 h, after which blood samples and liver, heart, and lung tissues were harvested. Results: In experiment I, 75% rats in the VEH group but only 25% rats in the LMK-235 and sirtinol groups died within ≤5 h of treatment, whereas the survival of rats in the MS-275, tubastatin A, and TSA groups was significantly prolonged. MS-275, LMK-235, tubastatin A, and TSA significantly reduced histopathological scores, apoptosis cell numbers, and inflammatory cytokine levels. In experiment II, the survival was longer after i.v. TSA treatment than after i.p. TSA treatment, and the IL-6 levels in the heart were significantly lower in rat who received i.p. TSA treatment than in those who received i.v. TSA treatment. Conclusions: The i.v. effect was superior to the i.p. effect, while nonselective and isoform-specific classes I and IIb HDACIs had similar effects.